What are the grading criteria for fatty liver steatosis on histology, ultrasound, FibroScan CAP, and MRI-PDFF, and how is fibrosis staged?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Grading of Fatty Liver

Hepatic steatosis should be graded using histology as the reference standard, with MRI-PDFF as the most accurate non-invasive quantitative method, while ultrasound serves as the recommended first-line screening tool despite its limitations in mild disease.

Histology Grading (Reference Standard)

Histological grading remains the gold standard for steatosis assessment 1:

  • Grade 0 (S0): <5% of hepatocytes containing fat vacuoles
  • Grade 1 (S1, mild): 5-33% of hepatocytes with fat
  • Grade 2 (S2, moderate): >33-66% of hepatocytes with fat
  • Grade 3 (S3, severe): >66% of hepatocytes with fat

This system provides the definitive classification against which all non-invasive methods are validated.

Ultrasound Grading

Conventional ultrasound is recommended as first-line for steatosis detection 2, though it has significant limitations:

Qualitative Grading 3:

  • Mild: Mild diffuse increase in liver echogenicity with clear definition of diaphragm and intrahepatic vessel walls
  • Moderate: Mild diffuse increase in liver echogenicity with obscuration of diaphragm and intrahepatic vessel walls
  • Severe: Marked increase in liver echogenicity with non-visualization of diaphragm and intrahepatic vessel walls

Performance Limitations:

Ultrasound performs well for moderate-severe steatosis (>30% fat content: 84.8% sensitivity, 93.6% specificity) but poorly for mild steatosis (sensitivity drops to 53.3-65%) 3. The 2021 EASL guidelines explicitly state that non-invasive scores are not recommended for steatosis diagnosis in clinical practice 2.

Quantitative Alternative - Hepatorenal Index:

The hepatorenal index offers superior performance for mild steatosis detection, with excellent correlation to MR spectroscopy and liver biopsy (AUC 99.2-99.6%), and is independent of confounding factors like BMI, inflammation, or fibrosis 3.

FibroScan CAP (Controlled Attenuation Parameter)

CAP values above 275 dB/m can diagnose steatosis with >90% sensitivity 2, though it cannot yet be recommended as first-line given limited availability:

Steatosis Grade Thresholds 4:

  • S1 (mild): 248 dB/m
  • S2 (moderate): 268 dB/m
  • S3 (severe): 280 dB/m

Performance data shows sensitivities/specificities of 78%/79% for S1, 85%/79% for S2, and 83%/79% for S3 3. A 2025 study in NAFLD patients found mean CAP of 271.53 dB/m (moderate steatosis), with patients having BMI ≥25 kg/m² being 3.7 times more likely to have severe steatosis (CAP ≥291 dB/m) 5.

MRI-PDFF (Proton Density Fat Fraction)

MRI-PDFF is the most accurate non-invasive method for detecting and quantifying steatosis 2, recommended primarily for clinical trials due to cost and availability:

Steatosis Grade Thresholds 4:

  • S1 (mild): 5% fat fraction
  • S2 (moderate): 11-18% fat fraction
  • S3 (severe): 16-23% fat fraction

Diagnostic Performance:

A 2017 multi-center NASH trial demonstrated excellent accuracy 6:

  • Grades 2-3 vs 0-1: AUROC 0.95 (cutoff 16.3% at 90% specificity, 83% sensitivity)
  • Grade 3 vs 0-2: AUROC 0.96 (cutoff 21.7% at 90% specificity, 84% sensitivity)

A 2012 study showed strong correlation (r² = 0.56) between MRI-PDFF and histology, with mean PDFF values of 8.9% (grade 1), 16.3% (grade 2), and 25.0% (grade 3) 7.

Critical caveat: Patients with advanced fibrosis (stage 4) had significantly lower steatosis by both MRI-PDFF (7.6% vs 17.8%) and histology, meaning low hepatic fat does not exclude advanced disease 7.

MRI-PDFF for Treatment Response:

PDFF reduction of ≥5.15% identifies histological steatosis improvement with 90% specificity and 58% sensitivity 6. The 2021 EASL guidelines support using MRI-PDFF to assess steatosis evolution under treatment 2.

Fibrosis Staging

Fibrosis stage, not steatosis grade, is the key predictor of liver-related outcomes and mortality 8:

Non-Invasive Fibrosis Assessment Strategy 2, 9, 8:

First-line screening with FIB-4:

  • Low risk (rule-out advanced fibrosis): FIB-4 <1.3 (or <2.0 if age >65)
  • Indeterminate risk: FIB-4 1.3-2.67
  • High risk: FIB-4 >2.67

Second-line testing for indeterminate/high-risk patients:

  • Transient elastography (TE): LSM <8 kPa rules out advanced fibrosis 2
  • Enhanced Liver Fibrosis (ELF): <9.8 rules out advanced fibrosis 2

MR Elastography (MRE):

MRE is the most accurate non-invasive fibrosis staging method 2, 4, though only marginally better than other NITs for F3-F4:

  • F2: 3.14 kPa
  • F3: 3.53 kPa
  • F4: 4.45 kPa

The MEFIB score (MRE + FIB-4) provides excellent diagnostic performance: MRE <3.3 kPa AND FIB-4 <1.6 rules out F2 fibrosis 4.

Clinical Pitfalls

  1. Normal liver enzymes do not exclude NAFLD or significant fibrosis - ALT >2× ULN has only 50% sensitivity for NASH and 40% for advanced fibrosis 8

  2. Ultrasound cannot reliably grade mild steatosis - sensitivity drops dramatically for <30% fat content 3, 1

  3. Low steatosis on imaging does not mean mild disease - advanced fibrosis patients often have paradoxically lower fat content 7

  4. FIB-4 has age-dependent cutoffs - use <2.0 (not <1.3) for patients >65 years to avoid false positives 9, 8

  5. Repeat assessment intervals: Every 1-3 years for low-risk patients, annually for advanced-stage NAFLD 2

References

Guideline

acr appropriateness criteria® abnormal liver function tests.

Journal of the American College of Radiology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.